NcXHF

PERIPHERAL NEUROTOXICITY IN CANCER SURVIVORS
11. Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral
neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol.
2012;82:51-77.
12. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral
neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12:
1151-1161.
13. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity.
Nat Rev Neurol. 2010;6:657-666.
14. Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patientreported
outcome measures in chemotherapy-induced sensory peripheral
neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25:257-264.
15. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root
ganglion neurons is associated with attempted entry into the cell cycle.
J Clin Invest. 1998;101:2842-2850.
16. Sprowl JA, Ciarimboli G, Lancaster CS, et al. Oxaliplatin-induced neurotoxicity
is dependent on the organic cation transporter OCT2. Proc
Natl Acad SciUSA.2013;110:11199-11204.
17. Cavaletti G, Ceresa C, Nicolini G, et al. Neuronal drug transporters in
platinum drugs-induced peripheral neurotoxicity. Anticancer Res. 2014;
34:483-486.
18. Park SB, Krishnan AV, Lin CS, et al. Mechanisms underlying
chemotherapy-induced neurotoxicity and the potential for neuroprotective
strategies. Curr Med Chem. 2008;15:3081-3094.
19. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric
analysis of paclitaxel and docetaxel-induced peripheral neuropathy
in rats. Eur J Cancer. 2005;41:1460-1466.
20. Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel
administration in the rat induces a peripheral sensory neuropathy
characterized by macrophage infıltration and injury to sensory neurons
and their supporting cells. Exp Neurol. 2007;203:42-54.
21. Jin HW, Flatters SJ, Xiao WH, et al. Prevention of paclitaxel-evoked
painful peripheral neuropathy by acetyl-l-carnitine: effects on axonal
mitochondria, sensory nerve fıber terminal arbors, and cutaneous Langerhans
cells. Exp Neurol. 2008;210:229-237.
22. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter
sensory neurons and myelinated axons in vincristine-induced painful
peripheral neuropathy in the rat. J Comp Neurol. 2000;424:563-576.
23. Carozzi VA, Renn CL, Bardini M, et al. Bortezomib-induced painful
peripheral neuropathy: an electrophysiological, behavioral, morphological
and mechanistic study in the mouse. PLoS One. 2013;8:e72995.
24. Meregalli C, Canta A, Carozzi VA, et al. Bortezomib-induced painful
neuropathy in rats: a behavioral, neurophysiological and pathological
study in rats. Eur J Pain. 2010;14:343-350.
25. Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation
of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in
sensory ganglia neurons. Neurotox Res. 2010:17:167-178.
26. Montagut C, Rovira A, Mellado B, et al. Preclinical and clinical development
of the proteasome inhibitor bortezomib in cancer treatment.
Drugs Today (Barc). 2005;41:299-315.
27. Poruchynsky MS, Sackett DL, Robey RW, et al. Proteasome inhibitors
increase tubulin polymerization and stabilization in tissue culture
cells: a possible mechanism contributing to peripheral
neuropathy and cellular toxicity following proteasome inhibition.
Cell Cycle. 2008;7:940-949.
28. Meregalli C, Chiorazzi A, Carozzi VA, et al. Evaluation of tubulin polymerization
and chronic inhibition of proteasome as citotoxicity
mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle.
2014;13:612-621.
29. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a
clinical and neurophysiologic study. Neurology. 2004;62:2291-2293.
30. Briani C, Torre CD, Campagnolo M, et al. Lenalidomide in patients with
chemotherapy-induced polyneuropathy and relapsed or refractory
multiple myeloma: results from a single-centre prospective study. J Peripher
Nerv Syst. 2013;18:19-24.
31. Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing
neuropathy caused by cisplatin and related compounds. Cochrane Database
Syst Rev. 2014;3:CD005228.
32. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management
of chemotherapy-induced peripheral neuropathy in survivors of
adult cancers: American Society of Clinical Oncology clinical practice
guideline. J Clin Oncol. 2014;32:1941-1967.
33. Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications
following alemtuzumab-based reduced-intensity allogeneic transplantation.
Bone Marrow Transplant. 2004;34:137-142.
34. Abbi KK, Rizvi SM, Sivik J, et al. Guillain-Barré syndrome after use of alemtuzumab
(Campath) in a patient with T-cell prolymphocytic leukemia: a
case report and review of the literature. Leuk Res. 2010;34:e154-e156.
35. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly
dosing study of brentuximab vedotin in patients with relapsed/refractory
CD30-positive hematologic malignancies. Clin Cancer Res.
2012;18:248-255.
36. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study
of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s
lymphoma. J Clin Oncol. 2012;30:2183-2189.
37. Pastorelli F, Derenzini E, Plasmati R, et al. Severe peripheral motor neuropathy
in a patient with Hodgkin lymphoma treated with brentuximab
vedotin. Leuk Lymphoma. 2013;54:2318-2321.
38. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin
treatment: challenging the dictum of reversibility. Oncologist.
2011;16:708-716.
39. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil
with or without oxaliplatin as fırst-line treatment in advanced colorectal
cancer. J Clin Oncol. 2000;18:2938-2947.
40. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil,
and leucovorin as adjuvant treatment for colon cancer. N Engl J Med.
2004;350:2343-2351.
41. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy
and its association with quality of life among 2- to 11-year colorectal
cancer survivors: results from the population-based PROFILES registry.
J Clin Oncol. 2013;31:2699-2707.
42. Beijers AJ, Mols F, Tjan-Heijnen VC, et al. Peripheral neuropathy in
colorectal cancer survivors: the influence of oxaliplatin administration.
Results from the population-based PROFILES registry. Acta Oncol.
Epub 2014 Nov 24.
43. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary.
FIGO 26th annual report on the results of treatment in gynecological
cancer. Int J Gynaecol Obstet. 2006;95 (suppl 1):S161-S192.
44. Stavraka C, Ford A, Ghaem-Maghami S, et al. A study of symptoms
described by ovarian cancer survivors. Gynecol Oncol. 2012;125:59-
64.
45. Mols F, Beijers T, Vreugdenhil G, et al. Chemotherapy-induced peripheral
neuropathy and its association with quality of life: a systematic review.
Support Care Cancer. 2014;22:2261-2269.
46. Tofthagen C, Donovan KA, Morgan MA, et al. Oxaliplatin-induced peripheral
neuropathy’s effects on health-related quality of life of colorectal
cancer survivors. Support Care Cancer. 2013;21:3307-3313.
47. Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced
peripheral neuropathy and its impact on health-related quality of life
among ovarian cancer survivors: results from the population-based
PROFILES registry. Gynecol Oncol. 2014; 135:510-517.
48. Tofthagen C, Visovsky C, Berry DL. Strength and balance training for adults
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e559